Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan 21;7(1):HEP16.
doi: 10.2217/hep-2019-0010.

Updates of colorectal cancer liver metastases therapy: review on DEBIRI

Giammaria Fiorentini  1 , Donatella Sarti  1 , Roberto Nani  2 , Camillo Aliberti  3 , Caterina Fiorentini  4 , Stefano Guadagni  5
Affiliations
Review

Updates of colorectal cancer liver metastases therapy: review on DEBIRI

Giammaria Fiorentini et al. Hepat Oncol. .

Abstract

Colorectal cancer is a worldwide public health issue, presenting an advanced stage at diagnosis in more than 20% of patients. Liver metastases are the most common metastatic sites and are not indicated for resection in 80% of cases. Unresectable colorectal cancer liver metastases that are refractory to systemic chemotherapy may benefit from transarterial chembolization with irinotecan-loaded beads (DEBIRI). Several studies show the safety and efficacy of DEBIRI for the treatment of colorectal cancer liver metastases. The development of transarterial chembolization and the introduction of new embolics have contributed to better outcomes of DEBIRI. This article reviews the current literature on DEBIRI reporting its use, efficacy in terms of tumor response and survival and side effects.

Keywords: CRC-LM; DEBIRI; colorectal cancer; liver metastases; liver resection.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.

References

    1. Gruber-Rouh T, Marko C, Thalhammer A. et al. Current strategies in interventional oncology of colorectal liver metastases. Br. J. Radiol. 89(1064), 20151060 (2016). - PMC - PubMed
    1. Jones RP, Malik HZ, Fenwick SW. et al. PARAGON II – a single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer. Eur. J. Surg.Oncol. 42(12), 1866–1872 (2016). - PubMed

    2. • First study of DEBIRI as neoadjuvant therapy.

    1. Levy J, Zuckerman J, Garfinkle R. et al. Intra-arterial therapies for unresectable and chemorefractory colorectal cancer liver metastases: a systematic review and meta-analysis. HPB (Oxford) 20(10), 905–915 (2018). - PubMed
    1. Lo CM, Ngan H, Tso WK. et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35(5), 1164–1171 (2002). - PubMed
    1. Lammer J, Malagari K, Vogl T. et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc. Intervent. Radiol. 33(1), 41–52 (2010). - PMC - PubMed

LinkOut - more resources